プロテインエンジニアリングの世界市場:プロテインエンジニアリング技術、製品(機器、サービス)、蛋白質種類、需要先、地域別分析

◆英語タイトル:Protein Engineering Market by Technology (Rational Protein Design, Irrational Protein Design), Product (Instrument, Services), Protein Type (Monoclonal Antibodies, Interferon, Growth Hormone), End User (Academics Institutes, CROs) - Global Forecast to 2020
◆商品コード:MAM-MD-3258
◆発行会社(調査会社):MarketsandMarkets
◆発行日:2015年3月24日
◆ページ数:156
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD4,650 ⇒換算¥511,500見積依頼/購入/質問フォーム
Multi User (Five User)USD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD7,150 ⇒換算¥786,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、プロテインエンジニアリングの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観、市場シェア分析、市場環境分析、技術別分析、製品別分析、蛋白質種類別分析、地域別分析、市場規模及び予測、競争状況、関連企業分析などの情報をお届けいたします。
【レポートの概要】

Developing Asian countries such as the China and India are lucrative markets for protein engineering, owing to increase in R&D investment by the biologics companies in these regions.

The report segments the global protein engineering market product, technology, protein type, end user, and region. Instruments accounted for the largest share of the global Protein engineering market, by product in 2014. However, services and software is expected to grow at the highest CAGR during the forecast period, owing to ongoing technological advancements in this segment.

Rational protein design accounted the largest share of protein engineering market, by technology in 2014. This large share is attributed to increase in adoption of this technique over irrational protein design.

Based on protein type, the market is categorized into monoclonal antibodies, insulin, erythropoietin, interferon, colony stimulating factor, growth hormones, coagulation factor, vaccines and others (interleukins, follicle stimulating hormones, enzyme replacement). Monoclonal antibodies is the largest as well as fastest growing segment of the protein engineering protein type market. This growth is attributed to the increase in adoption of them for various therapies such as cancer and autoimmune diseases.
On the basis of end user, the protein engineering market is categorized academic research institutes, pharmaceutical and biotechnology companies, and contract research organizations. Pharmaceutical and biotechnology companies is the largest and fastest-growing end user segment. The high growth rate of this segment can be attributed to technological advancements in protein engineering and the increase in R&D budgets in the pharmaceutical sector.

New and innovative product launches was the dominant strategy adopted by key industry participants to increase their market share and cater to unmet needs.
From an insight perspective, this research report focuses on qualitative data, market size, and growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats), winning imperatives, and burning issues. The report also offers market sizes and data on the growth of various segments in the industry. It focuses on emerging and high-growth segments, high-growth regions, and initiatives of governments. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the protein engineering market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 16
1.3 MARKET SEGMENTATION 16
1.3.1 MARKETS COVERED 16
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 18
1.5 LIMITATIONS 18
1.6 STAKEHOLDERS 18

2 RESEARCH METHODOLOGY 19
2.1 MARKET SIZE ESTIMATION 20
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 22
2.2.1 KEY DATA FROM SECONDARY SOURCES 23
2.2.2 KEY DATA FROM PRIMARY SOURCES 24
2.2.2.1 Key Industry Insights 24
2.2.3 ASSUMPTIONS FOR THE STUDY 25

3 EXECUTIVE SUMMARY 26

4 PREMIUM INSIGHTS 30
4.1 ATTRACTIVE OPPORTUNITIES IN THE PROTEIN ENGINEERING MARKET 30
4.2 PROTEIN ENGINEERING MARKET, BY END USER 31
4.3 PROTEIN ENGINEERING MARKET, BY TECHNOLOGY 32
4.4 PROTEIN ENGINEERING MARKET, BY PRODUCT 32
4.5 PROTEIN ENGINEERING MARKET GROWTH OPPORTUNITIES, BY REGION 33
4.6 LIFE CYCLE ANALYSIS, BY REGION 33

5 MARKET OVERVIEW 34
5.1 INTRODUCTION 35
5.1.1 EVOLUTION 35
5.2 MARKET DYNAMICS 36
5.2.1 DRIVERS 37
5.2.1.1 Increase in adoption of protein-based drugs over non-protein-based drugs 37
5.2.1.2 Reduction in overall timeline and cost for drug discovery 37
5.2.1.3 High prevalence rate of lifestyle diseases 37
5.2.1.4 Growth in funding for protein engineering 37
5.2.2 RESTRAINTS 38
5.2.2.1 Expensive and high-maintenance tools and instruments used in protein engineering 38
5.2.3 OPPORTUNITIES 39
5.2.3.1 Significant growth prospects in developing countries 39
5.2.3.2 Protein therapy as an alternative to gene therapy 39
5.2.3.3 Top-selling biologics drugs going off–patent in the near future 39
5.2.4 CHALLENGES 40
5.2.4.1 Need for qualified researchers and mandatory training in protein engineering increases cost of process 40
5.2.5 WINNING IMPERATIVE 41
5.2.5.1 Site-directed mutagenesis is a breakthrough technology augmenting the growth of the protein engineering market 41

6 INDUSTRY INSIGHTS 42
6.1 INTRODUCTION 42
6.2 SUPPLY CHAIN ANALYSIS 42
6.2.1 KEY INFLUENCERS 43
6.3 PORTER’S FIVE FORCES ANALYSIS 44
6.3.1 THREAT OF NEW ENTRANTS 44
6.3.2 THREAT OF SUBSTITUTES 44
6.3.3 BARGAINING POWER OF BUYERS 45
6.3.4 BARGAINING POWER OF SUPPLIERS 45
6.3.5 INTENSITY OF RIVALRY 45
6.4 STRATEGIC BENCHMARKING 45
6.4.1 NEW PRODUCT LAUNCHES 45

7 PROTEIN ENGINEERING MARKET, BY PRODUCT 47
7.1 INTRODUCTION 48
7.2 INSTRUMENTS 49
7.2.1 REAGENTS 51
7.3 SERVICES & SOFTWARE 53

8 PROTEIN ENGINEERING MARKET, BY TECHNOLOGY 55
8.1 INTRODUCTION 56
8.2 RATIONAL PROTEIN DESIGN 58
8.3 IRRATIONAL PROTEIN DESIGN 60

9 PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE 62
9.1 INTRODUCTION 63
9.2 MONOCLONAL ANTIBODIES 64
9.3 INSULIN 66
9.4 ERYTHROPOIETIN 68
9.5 INTERFERONS 70
9.6 COLONY STIMULATING FACTORS 71
9.7 GROWTH HORMONES 73
9.8 COAGULATION FACTORS 74
9.9 VACCINES 76
9.10 OTHER PROTEINS 77

10 PROTEIN ENGINEERING MARKET, BY END USER 79
10.1 INTRODUCTION 80
10.2 ACADEMIC RESEARCH INSTITUTES 81
10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 84
10.4 CONTRACT RESEARCH ORGANIZATIONS 85

11 PROTEIN ENGINEERING MARKET, BY REGION 87
11.1 INTRODUCTION 88
11.2 NORTH AMERICA 90
11.3 U.S. 93
11.3.1 CANADA 96
11.4 EUROPE 99
11.5 ASIA 102
11.5.1 CHINA 105
11.5.2 INDIA 107
11.5.3 JAPAN 109
11.5.4 REST OF ASIA (ROA) 111
11.6 ROW 113

12 COMPETITIVE LANDSCAPE 116
12.1 OVERVIEW 117
12.2 BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES WAS THE KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS 118
12.3 NEW PRODUCT LAUNCHES 118
12.4 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 119
12.5 EXPANSIONS 120
12.6 ACQUISITIONS 121

13 COMPANY PROFILES 122
(Overview, Financials, Products & Services, Strategy, & Developments)*
13.1 INTRODUCTION 122
13.2 AGILENT TECHNOLOGIES, INC. 123
13.3 BIO-RAD LABORATORIES, INC. 126
13.4 BRUKER CORPORATION 128
13.5 AB SCIEX (A SUBSIDIARY OF DANAHER CORPORATION) 131
13.6 GE HEALTHCARE 134
13.7 GENSCRIPT USA, INC. 136
13.8 PERKINELMER, INC. 138
13.9 SIGMA-ALDRICH CORPORATION 141
13.10 THERMO FISHER SCIENTIFIC, INC. 143
13.11 WATERS CORPORATION 146
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

14 APPENDIX 149
14.1 INSIGHTS OF INDUSTRY EXPERTS 149
14.2 DISCUSSION GUIDE 149
14.3 RECENT DEVELOPMENTS 151
14.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 153
14.5 AVAILABLE CUSTOMIZATIONS 154
14.6 RELATED REPORTS 155

LIST OF TABLES

TABLE 1 INCREASE IN ADOPTION OF PROTEIN-BASED DRUGS OVER NON-PROTEIN-BASED DRUGS AND HIGH PREVALENCE RATE OF LIFESTYLE DISEASES TO DRIVE THE PROTEIN ENGINEERING MARKET 38
TABLE 2 EXPENSIVE AND HIGH MAINTENANCE TOOLS AND INSTRUMENTS USED IN PROTEIN ENGINEERING RESTRAINING MARKET GROWTH 39
TABLE 3 DEVELOPING COUNTRIES PROVIDE SIGNIFICANT GROWTH OPPORTUNITIES FOR THE PROTEIN ENGINEERING MARKET 40
TABLE 4 DEARTH OF QUALIFIED RESEARCHERS AND NEED FOR MANDATORY TRAINING 40
TABLE 5 PROTEIN ENGINEERING MARKET SIZE, BY PRODUCT, 2013–2020 ($MILLION) 48
TABLE 6 PROTEIN ENGINEERING MARKET SIZE FOR INSTRUMENTS, BY REGION,
2013–2020 ($MILLION) 50
TABLE 7 NORTH AMERICA: PROTEIN ENGINEERING MARKET SIZE FOR INSTRUMENTS,
BY COUNTRY, 2013–2020 ($MILLION) 50
TABLE 8 ASIA: PROTEIN ENGINEERING MARKET SIZE FOR INSTRUMENTS,
BY COUNTRY/REGION, 2013–2020 ($MILLION) 50
TABLE 9 PROTEIN ENGINEERING MARKET SIZE FOR REAGENTS, BY REGION,
2013–2020 ($MILLION) 52
TABLE 10 NORTH AMERICA: PROTEIN ENGINEERING MARKET SIZE FOR REAGENTS,
BY COUNTRY, 2013–2020 ($MILLION) 52
TABLE 11 ASIA: PROTEIN ENGINEERING MARKET SIZE FOR REAGENTS,
BY COUNTRY/REGION, 2013–2020 ($MILLION) 52
TABLE 12 PROTEIN ENGINEERING MARKET SIZE FOR SERVICES AND SOFTWARE,
BY REGION, 2013–2020 ($MILLION) 53
TABLE 13 NORTH AMERICA: PROTEIN ENGINEERING MARKET SIZE FOR SERVICES AND SOFTWARE, BY COUNTRY, 2013–2020 ($MILLION) 54
TABLE 14 ASIA: PROTEIN ENGINEERING MARKET SIZE FOR SERVICES AND SOFTWARE,
BY COUNTRY/REGION, 2013–2020 ($MILLION) 54
TABLE 15 PROTEIN ENGINEERING MARKET SIZE, BY TECHNOLOGY, 2013–2020 ($MILLION) 57
TABLE 16 RATIONAL PROTEIN DESIGN MARKET SIZE, BY REGION, 2013–2020 ($MILLION) 59
TABLE 17 NORTH AMERICA: RATIONAL PROTEIN DESIGN MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 59
TABLE 18 ASIA: RATIONAL PROTEIN DESIGN MARKET SIZE, BY COUNTRY/REGION,
2013–2020 ($MILLION) 60
TABLE 19 IRRATIONAL PROTEIN DESIGN MARKET SIZE, BY REGION, 2013–2020 ($MILLION) 60
TABLE 20 NORTH AMERICA: IRRATIONAL PROTEIN DESIGN MARKET SIZE, BY COUNTRY, 2013–2020 ($MILLION) 61
TABLE 21 ASIA: IRRATIONAL PROTEIN DESIGN MARKET SIZE, BY COUNTRY/REGION,
2013–2020 ($MILLION) 61
TABLE 22 PROTEIN ENGINEERING MARKET SIZE, BY PROTEIN TYPE, 2013–2020 ($MILLION) 63
TABLE 23 MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2013–2020 ($MILLION) 65
TABLE 24 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 65
TABLE 25 ASIA: MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY/REGION,
2013–2020 ($MILLION) 65
TABLE 26 INSULIN MARKET SIZE, BY REGION, 2013–2020 ($MILLION) 66
TABLE 27 NORTH AMERICA: INSULIN MARKET SIZE, BY COUNTRY, 2013–2020 ($MILLION) 67
TABLE 28 ASIA: INSULIN MARKET SIZE, BY COUNTRY/REGION, 2013–2020 ($MILLION) 67
TABLE 29 ERYTHROPOIETIN MARKET SIZE, BY REGION, 2013–2020 ($MILLION) 68
TABLE 30 NORTH AMERICA: ERYTHROPOIETIN MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 69
TABLE 31 ASIA: ERYTHROPOIETIN MARKET SIZE, BY COUNTRY/REGION,
2013–2020 ($MILLION) 69
TABLE 32 INTERFERONS MARKET SIZE, BY REGION, 2013–2020 ($MILLION) 70
TABLE 33 NORTH AMERICA: INTERFERONS MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 70
TABLE 34 ASIA: INTERFERONS MARKET SIZE, BY COUNTRY/REGION, 2013–2020 ($MILLION) 71
TABLE 35 COLONY STIMULATING FACTORS MARKET SIZE, BY REGION,
2013–2020 ($MILLION) 72
TABLE 36 NORTH AMERICA: COLONY STIMULATING FACTORS MARKET SIZE,
BY COUNTRY, 2013–2020 ($MILLION) 72
TABLE 37 ASIA: COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 72
TABLE 38 GROWTH HORMONES MARKET SIZE, BY REGION, 2013–2020 ($MILLION) 73
TABLE 39 NORTH AMERICA: GROWTH HORMONES MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 73
TABLE 40 ASIA: GROWTH HORMONES MARKET SIZE, BY COUNTRY/REGION,
2013–2020 ($MILLION) 74
TABLE 41 COAGULATION FACTORS MARKET SIZE, BY REGION, 2013–2020 ($MILLION) 75
TABLE 42 NORTH AMERICA: COAGULATION FACTORS MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 75
TABLE 43 ASIA: COAGULATION FACTORS MARKET SIZE, BY COUNTRY/REGION,
2013–2020 ($MILLION) 75
TABLE 44 VACCINES MARKET SIZE, BY REGION, 2013–2020 ($MILLION) 76
TABLE 45 NORTH AMERICA: VACCINES MARKET SIZE, BY COUNTRY, 2013–2020 ($MILLION) 76
TABLE 46 ASIA: VACCINES MARKET SIZE, BY COUNTRY/REGION, 2013–2020 ($MILLION) 77
TABLE 47 OTHER PROTEINS MARKET SIZE, BY REGION, 2013–2020 ($MILLION) 78
TABLE 48 NORTH AMERICA: OTHER PROTEINS MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 78
TABLE 49 ASIA: OTHER PROTEINS MARKET SIZE, BY COUNTRY/REGION,
2013–2020 ($MILLION) 78
TABLE 50 GLOBAL PROTEIN ENGINEERING MARKET SIZE, BY END USER,
2013–2020 ($MILLION) 80
TABLE 51 PROTEIN ENGINEERING MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES,
BY REGION, 2013–2020 ($MILLION) 82
TABLE 52 NORTH AMERICA: PROTEIN ENGINEERING MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2013–2020 ($MILLION) 83
TABLE 53 ASIA: PROTEIN ENGINEERING MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY/REGION, 2013–2020 ($MILLION) 83
TABLE 54 PROTEIN ENGINEERING MARKET SIZE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2013–2020 ($MILLION) 84
TABLE 55 NORTH AMERICA: PROTEIN ENGINEERING MARKET SIZE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2013–2020 ($MILLION) 84
TABLE 56 ASIAN PROTEIN ENGINEERING MARKET SIZE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2013–2020 ($MILLION) 85
TABLE 57 PROTEIN ENGINEERING MARKET SIZE FOR CROS, BY REGION,
2013–2020 ($MILLION) 85
TABLE 58 NORTH AMERICA: PROTEIN ENGINEERING MARKET SIZE FOR CROS, BY COUNTRY, 2013–2020 ($MILLION) 86
TABLE 59 ASIA: PROTEIN ENGINEERING MARKET SIZE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2013–2020 ($MILLION) 86
TABLE 60 PROTEIN ENGINEERING MARKET SIZE, BY REGION, 2013–2020 ($MILLION) 89
TABLE 61 NORTH AMERICA: PROTEIN ENGINEERING MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 91
TABLE 62 NORTH AMERICA: PROTEIN ENGINEERING MARKET SIZE, BY PRODUCT,
2013–2020 ($MILLION) 91
TABLE 63 NORTH AMERICA: PROTEIN ENGINEERING MARKET SIZE, BY TECHNOLOGY,
2013–2020 ($MILLION) 91
TABLE 64 NORTH AMERICA: PROTEIN ENGINEERING MARKET SIZE, BY PROTEIN TYPE, 2013–2020 ($MILLION) 92
TABLE 65 NORTH AMERICA: PROTEIN ENGINEERING MARKET SIZE, BY END USER,
2013–2020 ($MILLION) 92
TABLE 66 U.S.: PROTEIN ENGINEERING MARKET SIZE, BY PRODUCT, 2013–2020 ($MILLION) 94
TABLE 67 U.S.: PROTEIN ENGINEERING MARKET SIZE, BY TECHNOLOGY,
2013–2020 ($MILLION) 94
TABLE 68 U.S.: PROTEIN ENGINEERING MARKET SIZE, BY PROTEIN TYPE,
2013–2020 ($MILLION) 95
TABLE 69 U.S.: PROTEIN ENGINEERING MARKET SIZE, BY END USER,
2013–2020 ($MILLION) 95
TABLE 70 CANADA: PROTEIN ENGINEERING MARKET SIZE, BY PRODUCT,
2013–2020 ($MILLION) 97
TABLE 71 CANADA: PROTEIN ENGINEERING MARKET SIZE, BY TECHNOLOGY,
2013–2020 ($MILLION) 97
TABLE 72 CANADA: PROTEIN ENGINEERING MARKET SIZE, BY PROTEIN TYPE,
2013–2020 ($MILLION) 98
TABLE 73 CANADA: PROTEIN ENGINEERING MARKET SIZE, BY END USER,
2013–2020 ($MILLION) 98
TABLE 74 EUROPE: PROTEIN ENGINEERING MARKET SIZE, BY PRODUCT,
2013–2020 ($MILLION) 100
TABLE 75 EUROPE: PROTEIN ENGINEERING MARKET SIZE, BY TECHNOLOGY,
2013–2020 ($MILLION) 100
TABLE 76 EUROPE: PROTEIN ENGINEERING MARKET SIZE, BY PROTEIN TYPE,
2013–2020 ($MILLION) 101
TABLE 77 EUROPE: PROTEIN ENGINEERING MARKET SIZE, BY END USER,
2013–2020 ($MILLION) 101
TABLE 78 ASIA: PROTEIN ENGINEERING MARKET SIZE, BY COUNTRY,
2013–2020 ($MILLION) 102
TABLE 79 ASIA: PROTEIN ENGINEERING MARKET SIZE, BY PRODUCT,
2013–2020 ($MILLION) 103
TABLE 80 ASIA: PROTEIN ENGINEERING MARKET SIZE, BY TECHNOLOGY,
2013–2020 ($MILLION) 103
TABLE 81 ASIA: PROTEIN ENGINEERING MARKET SIZE, BY PROTEIN TYPE,
2013–2020 ($MILLION) 104
TABLE 82 ASIA: PROTEIN ENGINEERING MARKET SIZE, BY END USER,
2013–2020 104
TABLE 83 CHINA: PROTEIN ENGINEERING MARKET SIZE, BY PRODUCT,
2013–2020 ($MILLION) 105
TABLE 84 CHINA: PROTEIN ENGINEERING MARKET SIZE, BY TECHNOLOGY,
2013–2020 ($MILLION) 105
TABLE 85 CHINA: PROTEIN ENGINEERING MARKET SIZE, BY PROTEIN TYPE,
2013–2020 ($MILLION) 106
TABLE 86 CHINA: PROTEIN ENGINEERING MARKET SIZE, BY END USER,
2013–2020 ($MILLION) 106
TABLE 87 INDIA: PROTEIN ENGINEERING MARKET SIZE, BY PRODUCT,
2013–2020 ($MILLION) 107
TABLE 88 INDIA: PROTEIN ENGINEERING MARKET SIZE, BY TECHNOLOGY,
2013–2020 ($MILLION) 108
TABLE 89 INDIA: PROTEIN ENGINEERING MARKET SIZE, BY PROTEIN TYPE,
2013–2020 ($MILLION) 108
TABLE 90 INDIA: PROTEIN ENGINEERING MARKET SIZE, BY END USER,
2013–2020 ($MILLION) 109
TABLE 91 JAPAN: PROTEIN ENGINEERING MARKET SIZE, BY PRODUCT,
2013–2020 ($MILLION) 109
TABLE 92 JAPAN: PROTEIN ENGINEERING MARKET SIZE, BY TECHNOLOGY,
2013–2020 ($MILLION) 110
TABLE 93 JAPAN: PROTEIN ENGINEERING MARKET SIZE, BY PROTEIN TYPE,
2013–2020 ($MILLION) 110
TABLE 94 JAPAN: PROTEIN ENGINEERING MARKET SIZE, BY END USER,
2013–2020 ($MILLION) 111
TABLE 95 ROA: PROTEIN ENGINEERING MARKET SIZE, BY PRODUCT,
2013–2020 ($MILLION) 111
TABLE 96 ROA: PROTEIN ENGINEERING MARKET SIZE, BY TECHNOLOGY,
2013–2020 ($MILLION) 111
TABLE 97 ROA: PROTEIN ENGINEERING MARKET SIZE, BY PROTEIN TYPE,
2013–2020 ($MILLION) 112
TABLE 98 ROA: PROTEIN ENGINEERING MARKET SIZE, BY END USER,
2013–2020 ($MILLION) 112
TABLE 99 ROW: PROTEIN ENGINEERING MARKET SIZE, BY PRODUCT,
2013–2020 ($MILLION) 113
TABLE 100 ROW: PROTEIN ENGINEERING MARKET SIZE, BY TECHNOLOGY,
2013–2020 ($MILLION) 114
TABLE 101 ROW: PROTEIN ENGINEERING MARKET SIZE, BY PROTEIN TYPE,
2013–2020 ($MILLION) 114
TABLE 102 ROW: PROTEIN ENGINEERING MARKET SIZE, BY END USER,
2013–2020 ($MILLION) 115
TABLE 103 NEW PRODUCT LAUNCHES, 2012–2015 118
TABLE 104 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2012–2015 119
TABLE 105 EXPANSIONS, 2012–2015 120
TABLE 106 ACQUISITIONS, 2012–2015 121


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 19
FIGURE 2 MARKET SIZE ESTIMATION 21
FIGURE 3 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 22
FIGURE 4 DATA TRIANGULATION METHODOLOGY 23
FIGURE 5 PROTEIN ENGINEERING MARKET SNAPSHOT (2014 VS. 2020): SOFTWARE AND SERVICES TO BE THE FASTEST-GROWING SEGMENT IN THE NEXT FIVE YEARS 26
FIGURE 6 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES WILL CONTINUE TO DOMINATE THE PROTEIN ENGINEERING MARKET DURING THE FORECAST PERIOD 27
FIGURE 7 PROTEIN ENGINEERING TECHNOLOGY MARKET SNAPSHOT (2014 VS. 2019): RATIONAL DESIGN TO WITNESS HIGHEST GROWTH RATE IN THE NEXT FIVE YEARS 27
FIGURE 8 ASIA EXPECTED TO BE THE FASTEST-GROWING MARKET DURING THE FORECAST PERIOD 28
FIGURE 9 NEW PRODUCT LAUNCHES WAS THE MAJOR STRATEGY ADOPTED BY INDUSTRY PLAYERS 29
FIGURE 10 MARKET GROWTH WILL BE DRIVEN BY INCREASING ADOPTION OF BIOLOGICS 30
FIGURE 11 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ACCOUNTED FOR THE LARGEST SHARE IN 2014 31
FIGURE 12 RATIONAL PROTEIN DESIGN IS EXPECTED TO DOMINATE THE TECHNOLOGY MARKET DURING THE FORECAST PERIOD 32
FIGURE 13 SOFTWARE AND SERVICES SEGMENT HOLDS LUCRATIVE GROWTH OPPORTUNITIES 32
FIGURE 14 ASIA TO WITNESS THE HIGHEST GROW RATE FROM 2015 TO 2020 33
FIGURE 15 ASIA HOLDS LUCRATIVE GROWTH OPPORTUNITIES 33
FIGURE 16 PROTEIN ENGINEERING MARKET: TECHNOLOGICAL EVOLUTION 35
FIGURE 17 PROTEIN ENGINEERING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 36
FIGURE 18 DIRECT DISTRIBUTION—STRATEGY PREFERRED BY PROMINENT COMPANIES 43
FIGURE 19 REQUIREMENT OF HIGH CAPITAL INVESTMENT TO RESTRICT ENTRY OF NEW PLAYERS 44
FIGURE 20 MARKET LEADERS ADOPTED THE ORGANIC GROWTH STRATEGY OF NEW PRODUCT LAUNCHES 46
FIGURE 21 INSTRUMENTS EXPECTED TO BE THE LARGEST SEGMENT IN FORECAST PERIOD 48
FIGURE 22 NORTH AMERICA WILL CONTINUE TO LEAD PROTEIN ENGINEERING INSTRUMENTS MARKET FOR THE FORECAST PERIOD (2015-2020) 49
FIGURE 23 ASIAN REAGENTS SEGMENT TO SHOW FASTEST GROWTH 51
FIGURE 24 SNAPSHOT: RATIONAL AND IRRATIONAL PROTEIN DESIGN 56
FIGURE 25 RATIONAL PROTEIN DESIGN SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN THE FORECAST PERIOD 57
FIGURE 26 NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE IN THE RATIONAL PROTEIN DESIGN MARKET 58
FIGURE 27 MONOCLONAL ANTIBODIES WILL CONTINUE TO DOMINATE THE MARKET IN THE FORECAST PERIOD 64
FIGURE 28 NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE IN THE INSULIN MARKET 66
FIGURE 29 NORTH AMERICA COMMANDED THE LARGEST SHARE OF THE ERYTHROPOIETIN MARKET IN 2014 68
FIGURE 30 ASIA IS THE FASTEST-GROWING SEGMENT OF THE CSF MARKET 71
FIGURE 31 ASIA IS THE FASTEST GROWING MARKET FOR THE FORECAST PERIOD 74
FIGURE 32 NORTH AMERICA COMMANDED THE LARGEST SHARE OF OTHERS MARKET IN 2014 77
FIGURE 33 BROAD END-USER BASE OF PROTEIN ENGINEERING 80
FIGURE 34 IN 2014, PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES SEGMENT WAS THE LARGEST AND FASTEST-GROWING END-USER 81
FIGURE 35 NORTH AMERICA DOMINATES THE PROTEIN ENGINEERING MARKET FOR ACADEMIC RESEARCH INSTITUTES 82
FIGURE 36 ASIA WILL BE THE FASTEST-GROWING MARKET BY 2020 88
FIGURE 37 ASIA—AN ATTRACTIVE DESTINATION FOR PROTEIN ENGINEERING 89
FIGURE 38 GOVERNMENT FUNDING AND TECHNOLOGY ADVANCEMENTS TO DRIVE DEMAND FOR PROTEIN ENGINEERING 90
FIGURE 39 RATIONAL DESIGN SEGMENT WILL CONTINUE TO LEAD THE PROTEIN ENGINEERING TECHNOLOGIES MARKET IN THE U.S. 93
FIGURE 40 RATIONAL PROTEIN DESIGN TECHNOLOGY SEGMENT EXPECTED TO GROW AT THE HIGHEST RATE FROM 2015 TO 2020 96
FIGURE 41 EUROPEAN PROTEIN ENGINEERING MARKET SNAPSHOT 99
FIGURE 42 JAPAN WILL CONTINUE TO DOMINATE THE ASIAN PROTEIN ENGINEERING MARKET IN THE FORECAST PERIOD 102
FIGURE 43 INSTRUMENTS SEGMENT TO WITNESS THE HIGHEST GROWTH IN THE ROW REGION 113
FIGURE 44 COMPANIES ADOPTED NEW PRODUCT LAUNCHES AS THEIR KEY GROWTH STRATEGY OVER THE LAST THREE YEARS 117
FIGURE 45 GEOGRAPHIC REVENUE MIX OF TOP 4 MARKET PLAYERS 122
FIGURE 46 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 123
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 126
FIGURE 48 BRUKER CORPORATION: COMPANY SNAPSHOT 128
FIGURE 49 DANAHER CORPORATION: COMPANY SNAPSHOT 131
FIGURE 50 GENERAL ELECTRIC: COMPANY SNAPSHOT 134
FIGURE 51 GENSCRIPT USA, INC.: COMPANY SNAPSHOT 136
FIGURE 52 PERKINELMER, INC.: COMPANY SNAPSHOT 138
FIGURE 53 SIGMA-ALDRICH CORPORATION: COMPANY SNAPSHOT 141
FIGURE 54 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT 143
FIGURE 55 WATERS CORPORATION: COMPANY SNAPSHOT 146


【レポートのキーワード】

プロテインエンジニアリング機器、プロテインエンジニアリング試薬、プロテインエンジニアリングサービス、プロテインエンジニアリングソフトウェア、プロテインエンジニアリング技術、モノクローナル抗体、インシュリン、エリトロポエチン、インターフェロン、コロニー刺激因子
成長ホルモン、凝固因子、ワクチン、蛋白質


【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[プロテインエンジニアリングの世界市場:プロテインエンジニアリング技術、製品(機器、サービス)、蛋白質種類、需要先、地域別分析]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。H&I文字はH&Iグローバルリサーチ株式会社の商標(登録第5783645号)です。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。
※当サイトでは2016年05月28日現在 190,379 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆